P2-283: Dose individualization of Carboplatin in elderly patients with advanced non small cell lung cancer (ANSCLC): an exploratory analysis  by Merino, Matilde et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS684
P2-281 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
Retrospective study on patients diagnosed with advanced 
Non-Small Cell Lung Cancer treated with the combination of 
gemcitabine and vinorelbine: assessment of therapeutic efficacy 
and prognosis factors
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Introduction: Gemcitabine (G), vinorelbine (V) and their combination 
(GV) have shown to be useful in patients with Non-Small Cell Lung 
Cancer (NSCLC). The purpose of this study has been to conﬁrm the 
effectiveness (activity) of GV and to identify prognostic factors related 
with clinical outcomes.
Methods: A retrospective analysis was carried out relating to 144 pa-
tients with NSCLC treated between October 1996 and April 2005 with 
G (1000-1250 mg/m2) +V (25-30 mg/m2) both administered on days 1 
and 8 every three weeks.
Results: Treatment was well tolerated neutropenia grade 3-4 being reg-
istered as the worse toxicity in 18% of cases, including 7% of neutrope-
nic fever. The objective response rate was 36.8% (95% CI: 28.9-44.7) 
and the median progression free survival and overall survival rates 
were 21 (18-25) and 33 (26-40) weeks respectively. In multivariate 
analysis only the histology of adenocarcinoma (HR 3; p<.0001), less 
than two metastatic sites (HR 1.7; p =.02)and Karnofsky index (KI) 
above 70 % (HR 1.5; p=.02) showed a signiﬁcant association with 
longer survival.
Conclusion: The combination of GV is well tolerated and active in 
patients with advanced NSCLC. The histology of adenocarcinoma, less 
than two metastatic sites and KI above 70 % have been identiﬁed as 
independent variables related with longer survival.
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Gemcitabine and vinorelbine combination as second-line therapy in 
previously taxane and platinum-treated non-small cell lung cancer
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Background: Gemcitabine (G) and vinorelbine (V) combination 
showed tolerable toxicities with response rate of 10-30% as second-line 
chemotherapy at several phase II studies. We evaluated its efﬁcacy and 
toxicity in previously taxane and platinum-treated refractory NSCLC. 
Methods: From July 2004 to February 2007, 25 evaluable patients 
were enrolled. All patients were refractory or resistant NSCLC after 
taxane and platinum combination as ﬁrst-line therapy for advanced 
NSCLC and ECOG PS 0-2. Treatment consisted of gemcitabine 1000 
mg/m2 plus vinorelbine 25 mg/m2 i.v. on days 1 & 8 of a 21-day cycle. 
Results: Among a total of 25 patients, 23 patients were evaluable for 
response and all 25 patients for toxicity. Median age was 58 years 
(range 44-79) and gender ratio was 19 males/6 females. Objective 
responses were seen in 5 of 23 evaluable patients (22%). four patients 
(18%) had stable disease and 14 patients (60%) progressive disease. 
Median overall survival was 5.3 months. A median of 2 cycles per 
patients were administered (range 1-8). The median delivered dose was 
538.5 mg/m2/week of gemcitabine and 13.3 mg/m2/week of vinorelbine 
and relative dose intensity was 81% and 80%, respectively. Grade 3/4 
neutropenia occurred in 68% but, febrile neutropenia only occurred in 
12%. Nausea, vomiting, anorexia, neuropathy and liver dysfunction 
were mild in most of patients. Grade 3 asthenia occurred in 20%. There 
was no predictive factor for tumor response of second-line therapy. For 
univariate analysis for overall survival, the responder of ﬁrst-line, good 
performance status, and disease-stabilized patients of GV chemothera-
py were signiﬁcantly analyzed (p<0.05). 
Conclusions: Gemcitabine and vinorelbine combination therapy 
showed modest efﬁcacy with disease stability of 40% and tolerable 
toxicity proﬁle in patients with previously taxane and platinum-treated 
refractory NSCLC. 
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Background: Application of population pharmacokinetic modelling 
to the routine therapeutic drug monitoring in elderly patients help to 
individualize the dosage of anticancer drugs. The aim of this study was 
to explore, by means of the individual pharmacokinetic parameters, 
the Calvert’s formula bias for establishing the Carboplatin (Cb) dose in 
elderly patients. Creatinine (Cr) Cl was calculated by Cockdroft-Gault 
equation.
Methods: Between December 2005 and September 2006, 19 chemona-
ive ANSCLC patients were included in two groups: 9 adult patients < 
65 years and 10 aged patients > 75 years. Treatment consisted in Cb 
day 1 and gemcitabine 1250 mg/m2 days 1 and 8 every 21 days. Cb 
dose was calculated for a foreseen AUC= 5 in young adults and AUC= 
4 in aged patients. Three blood samples were collected between 1-2 
hours (h), 3-5 h and 12-24 h post infusion. Ultraﬁltrated Carboplatin 
(Cbu) was determined using a ﬂameless atomic absorption spectrom-
eter. For pharmacokinetic analysis non lineal effects models imple-
mented in NONMEM program were used. Individual pharmacokinetic 
parameters were calculated and predictors in the structural model were 
analysed. 
Results: Mean and variation coefﬁcient of some biometric characteris-
tics and pharmacokinetic (PK) parameters are as follow:
 
Group
Cb  
Administered 
Dose (mg)
Age  
(years)
Cbu Cl 
Calvert 
(mL/min)
Cbu Cl 
Estimated 
(mL/min)
Cbu  
Calculated 
Dose (mg)
Young 662(23.4) 58(7.51) 129.62(25.2) 137(15.1) 741(19.9)
Elderly 323(16.1) 77.7(1.88) 81.61(8.21) 59.7(15.1) 234(20.9)
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Cbu Cl estimated in elderly patients was 43.55% with respect to 
younger patients. Besides, the Cbu Cl estimated was 5.69 % higher and 
26.85 % lower than the Cbu Cl calculated using the Calvert equation 
for young and elderly patients groups respectively.
Conclusions: The Cbu Cl calculation by means of Calvert formula 
showed under-estimation of the dose to administer at younger patients 
and upper-estimation of the dose to elderly patients. It is necessary to 
study the covariates which contribute to take away the strength of the 
Calvert equation, because affect the efﬁcacy and toxicity of Carbopla-
tin. 
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First-line treatment with vinorelbine (VRL) plus gemcitabine 
(GEM) for elderly patients with advanced non-small-cell lung 
cancer (NSCLC): Molecular correlates
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Background: The clinical beneﬁt of non-cisplatin doublets vs a single 
agent in elderly or unﬁt p is still controversial. The present study 
focuses on clinical outcome with VRL/GEM in elderly p and the role 
of functional status and comorbidities. Genetic predictive markers of 
response to VRL/GEM will also be examined in genomic and cDNA 
from tumor and circulating tumor DNA.
Methods: 145 chemonaive p with stage IIIB (pleural effusion or 
supraclavicular lymph nodes)-IV or recurrent NSCLC and age > 70 
years were accrued at 32 sites between April 2004 and January 2006. 
Treatment consisted of VRL 25 mg/m2 IV or 60-80 mg/m2 oral plus 
GEM 1200 mg/m2, days 1, 8 every 21 days. Activities of daily living 
(ADL), instrumental activities of daily living (IADL) and comorbidi-
ties were evaluated. DNA samples were collected from primary tumors 
for the assessment of microtubule associated protein 4 (MAP4) and 
from serum for the checkpoint with forkhead-associated and ring ﬁnger 
(CHFR) methylation.
Results: Data on 130 p is available for toxicity and 95 for response. 
Median age 76 years (69-83); males: 86.8%; smokers: 70.5%; PS 0-1: 
83.9%; adenocarcinoma: 34.4% / squamous: 48%; stage IIIB: 22.7%, 
IV: 77.3%. Self-sufﬁciency in ADL and IADL was 77.4% and 45.2% 
of the p analyzed. 68% of the p had comorbidities. Median cycles: 3 
(1-8). 461 cycles were performed, 16.3% were delayed and 2.1% had 
dose reduction. Hematological toxicities (%p): grade 3/4 neutropenia, 
7.8%/4.7%; grade 3/4 thrombocytopenia, 2.3%/0.8%; grade 3 anemia, 
3.1%. Efﬁcacy in evaluable population: PR, 23.2% (95% CI, 15.1% to 
32.9%); SD, 41.1%. 24 p died during the treatment period (non toxicity 
related) and 21 p were not evaluable. With a median follow up of 5.8 
months, median survival for the whole population was 4.97 months 
(m), progression free survival 4.53 m, event free survival 3.43 m, 1-
year survival 26.6%. Statistically signiﬁcant differences in median sur-
vival were observed among subgroups: PS 0-1/2, 6.5/2.3 m (p<0.001); 
sex male/female, 4.5/9.7 m (p 0.027); ADL <6/=6, 3.4/7.1 m (p 0.023).
Conclusions: This trial conﬁrms that VRL/GEM is effective, present-
ing a favourable response/toxicity ratio in elderly p with advanced 
NSCLC. Complete data on genetic markers will be presented. 
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or metastatic lung cancer: a preliminary report from a single-
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Background: Recent experimental studies have suggested that chronic 
administration of comparatively low doses of cytotoxic drugs at close, 
regular intervals, with no prolonged drug-free interruptions, known as 
“metronomic chemotherapy”, may target tumor-associated endothelial 
cells and can induce clinical meaningful effect in selected patients with 
solid tumors. 
Purpose: We report initial results of compassionate use of metronomic 
cyclophosphamide (50 mg p.o. daily until clinical disease progres-
sion or any grade 3-4 toxicity) in patients with advanced or metastatic 
lung cancer pre-treated with at least one platinum-based regimen and 
deemed unﬁt to further cytotoxic therapy.
Results: Data on sixteen patients enrolled between January 2005 and 
June 2006 are evaluable: most had a Karnofsky performance status of 
70% (10 pts), metastatic disease (9 pts), and 14 were pre-treated with 
a cisplatin/vinorelbine regimen; 15 had progressive disease at study 
entry, and 9 had progressive disease during the last therapy. One patient 
interrupted treatment due to recurrent grade-2 bladder hemorrhage. We 
noticed 2 partial remission (PR) (12%, 95% CI 0-28%) and 9 stable 
disease (SD) (56%, 95% CI 32-80%); the clinical beneﬁt rate (PR 
plus SD for > or = 24 weeks) in all pts were 44% (95% CI, 19-68%). 
Median survival was 11.9 months (95% CI 2.3-21.5 mo.) and 1-year 
survival rate was 47.7%. 
Conclusion: Metronomic cyclophosphamide chemotherapy is effective 
and minimally toxic in pre-treated lung cancer patients. 
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Background: Along with an acceptable tolerability proﬁle, single 
agent oral vinorelbine has shown to be effective in elderly NSCLC 
p. The oral formulation avoids the side effects associated with the IV 
injection, may reduce administration and toxicity-related costs and is 
easy to administer. Due to these advantages, single agent oral vinorel-
